Tag: cause

GUANGZHOU, China, June 09, 2026 (GLOBE NEWSWIRE) -- EHang Holdings Limited (Nasdaq: EH) (“EHang” or the “Company”), the world’s leading advanced air mobility (“AAM”) technology platform company, today announced its unaudited financial results for the first quarter ended March 31, 2026.

Progress on share buyback programme

HOUSTON, June 09, 2026 (GLOBE NEWSWIRE) -- VAALCO Energy, Inc. (NYSE: EGY, LSE: EGY) (“Vaalco” or the “Company”) announced that the Baobab field on CI-40 block, offshore Côte d’Ivoire is back online following the successful Baobab Ivoirien Floating Production Storage and Offloading vessel (“FPSO”) refurbishment.

SHANGHAI, June 09, 2026 (GLOBE NEWSWIRE) -- NIO Inc. (NYSE: NIO; HKEX: 9866; SGX: NIO) (“NIO” or the “Company”), a pioneer and a leading company in the global smart electric vehicle market, today noted that the U.S. Department of Defense has added the Company to its “Chinese military companies” list (the “CMC List”).

苏格兰格拉斯哥, June 09, 2026 (GLOBE NEWSWIRE) -- 万益特（Vantive），作为一家拥有70年肾脏护理创新历史的重要脏器疗法公司，今日发布两项突破性临床研究：采用 泰诺佳^® 透析器的 HDx 疗法，与在线血液透析滤过（OL-HDF）相比，在全因死亡率和主要心血管结局方面*表现相似（统计学上非劣效）。^1,2随机对照试验MOTheR 研究、真实世界研究CONCORDIA中期数据，已于 2026 年 6 月 3–6 日在苏格兰格拉斯哥举办的第 63届欧洲肾脏协会（ERA）大会上发布。

CNBC interview explores GLP-1 weight loss adoption, clinically backed nutrition, preventative health and the evolving consumer wellness landscape

NEW YORK, June 08, 2026 (GLOBE NEWSWIRE) -- Cipher Digital Inc. (NASDAQ: CIFR) (“Cipher” or the “Company”) a leading developer, owner, and operator of industrial-scale data centers, today announced that its wholly-owned subsidiary, Stingray Compute LLC (the “Issuer”), has priced a $810.0 million offering of 6.000% senior secured notes due 2031 (the “Notes”) at a price equal to 99.750% of their principal amount. The Notes will be sold in a private offering to persons reasonably believed to be qualified institutional buyers in reliance on Rule 144A under the Securities Act of 1933, as amended (the “Securities Act”) and to non-U.S. persons outside of the United States pursuant to Regulation S under the Securities Act. The offering is expected to close on June 15, 2026, subject to customary closing conditions.

COPENHAGEN, Denmark, June 08, 2026 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced that the latest data from its Endocrinology Rare Disease programs in hypoparathyroidism, achondroplasia, and pediatric growth hormone deficiency will be shared in two oral presentations and three posters at ENDO 2026, the annual meeting of the Endocrine Society being held in Chicago from June 13-16, 2026.